ErbB2/HER-2 and other molecular pathways in estrogen-receptorpositive breast cancer: Impact on endocrine resistance and clinical outcome

Advances in Endocrine Therapy of Breast Cancer: Proceedings of the 2003 Gleneagles Conference

Volumn , Issue , 2004, Pages 229-248

  Benz, Christopher C ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845432538     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (42)

1. Eppenberger-Castori S. Moore DH. Thor AD. Edgerton SM. Kueng W. Eppenberger U. Benz CC. Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 2002: 34:1318-1330.
2. Krtolica A. Parrinello S. Lockett S. Desprez P. Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci USA 2001:12072-12077.
3. Quong J. Eppenberger-Castori S. Moore II D. Scott GK. Birrir MJ. Kueng W. Eppenberger U. Benz CC. Age-dependent changes in breast cancer hormone receptors and oxidant stress markers. Breast Cancer Res Treat 2002: 76:221-236.
4. Osborne CK. Bardou V. Hopp TA. Chamness GC. Hilsenbeck SG. Fuqua SAW. Wong J. Allred DC. Clark GM. Schiff R. Role of the estrogen receptor coactivator AIBI (SRC-3) and HER2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003:95:353-361.
5. Gunnarsson C. Ahnstrom M. Kirschner K. Olsson B. Nordenskjold B. Rutquist LE. Skoog L. Stal O. Amplification of HSDI7B1 and ERBB2 in primary breast cancer Oncogene 2003; 22:34-40.
6. Tripathy D., Benz C. Growth factors and their receptors. In:Shapiro CL. Henderson IC. Eds. New Directions in Breast Cancer Research and Therapeutics. Hematology/Oncologx Clinics of North America. Philadelphia: WB Saunders. 1994. Pp. 29-50.
7. Benz C, Tripathy D. Erbb2 overexpression in breast cancer: biology and clinical translation. J Womens Cancer 2000; 2:33-40.
8. Smith CL. Cross-talk between peptide grow th factor and estrogen receptor signaling pathways. Biol Reprod 1998: 58:627-632.
9. Sommer S. Fuqua SAW. Estrogen receptor and breast cancer. Cancer Biol 2001: 11339-352.
10. Ressell KS. Hung M-C. Transcriptional repression of the neu protooncogene b\ estrogen stimulated estrogen receptor. Cancer Res 1992: 52:6624-6629.
11. DeFazio A. Chiew YE. Mcevoy M. Walts CK. Sutherland RL. Antisense estrogen receptor RNA expression increases epidermal grow th factor receptor gene expression in breast cancer cells. Cell Grow th Differ 1997; 8:903-911.
12. Newman SP. Baies NP. Vernimmen D. Parker MO. Hursi HC. Cofacior eompetilion between the ligand-bound oestrogen reeeptor and an intron I enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 2000: 19:490-497.
13. Eppenberger-Castori S. Kueng VV. Benz CC. Paris K. Caduff R. Bannwart F. Fink D. Dieterich H. Brasehler C. Von Castelberg B. Muller H. Eppenberger U. Prognostic and predictive significance ot ErbB2 breast tumor levels measured by enzyme-immunoassav (EIA). J Clin Oncol 2001: 19:645-656.
14. Konecny G. Pauletti G. Pegram M. Untch M. Dandekar S. Aguilar Z. Wilson C. Rong H-M. Bauerteind I. Felber M. Wang H-J. Beryt M. Seshadri R. Hepp FI. Slamon DJ. Quantitative association between HER2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003: 95:142-153.
15. Bern DA., Muss HB., Thor AD., Dressier L., Liu ET., Broadwater G., Budman DR., Henderson IC., Barcos M., Hayes D., and Norton L., HER2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000: 18:3471-3479.
16. DePlacido S. De Laurentiis M. Carlomagno C. Gallo C. Perrone F. Pepe S. Ruggiero A. Marinelli A. Pagharulo C. Panieo L. Pettinato G. Petrella G. Bianco AR. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003: 9:1039-1046.
17. Ring A. Dowsett M. Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications. Clin Breast Cancer 2003: 4(suppl 1):S34-S41.
18. DeLaurentiis M., Arpino G, Massarelli E., Carlomagno C., Ciardiello F., Tortora G., Bianco AR., DePlacido S., A meta-analysis of the interaction between HER2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC) [abstr]. Proc Am Soc Clin Oncol 2000:19:78.
19. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer. November 1-3. 2000. J Nall Cancer Inst Monographs 2001; 30:5-15.
20. Winer EP. Hudis C. Burstein HJ. Chlebowski RT. Ingle JN. Edge SB. Mamounas EP. Gralovv J. Goldstein LJ. Pritchard KI. Braun S. Cobleigh MA. Langer AS. Perotti J. Powles TJ. Whelan TJ. Brownian GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002; 20: 3317-3327.
21. Benz CC. Scott GK. Sarup JC. Johnson RM. Tripathy D. Coronado E. Shepard HM. Osborne CK. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992; 24:85-95.
22. Ellis MJ. Coop A. Singh B. Mauriac L. Llombert-Cussac A. Janicke F. Miller WR. Evans DB. Dugan M. Bradv C. Quebe-Fehling E. Borgs M. Letrozole is a more effective neoadjuvant endocrine therapy than tamoxifen for ErbBI- and/or ErbB2-posilive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-3816.
23. Kurokawa H. Lenferink AEG. Simpson JF. Pisacane PL Sliwkowski MX. Forbes JT. Arteaga CL. Inhibition of HER2/neu (ErbB2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing. Tamoxifen-resistant breast cancer cells. Cancer Res 2000; 5887-5894.
24. Massarxveh S., Shou J., Mohsin SK., Ge M., Wakeling AE., Osborne CK and Schiff R., Inhibition of epidermal growth factor/HER2 receptor signaling using ZD 1839 (Iressa) restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumors [abstr], Proc Am Soc Clin Oncol 2002; 21:33a.
25. Kunisue H., Kurebayashi J., Otsuki T., Tang CK., Kurosumi M., Yamamoto S., Tanaka K., Doihara H, Shimizu N., Sonoo H. Anti-HER2 antibody enhances the growth inhibitory effect of anti-estrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br J Cancer 2000: 82:46-51.
26. Schiff R. Massarweh S. Shou J. Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 2003: 9:447s-454s.
27. Kurokawa H, Arteaga CL. Erbb (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 2003: 9:511s-515s.
28. Johnston SRD., Head J., Pancholi S, Detre S., Martin L-A., Smith IE., Dowsett M., Integration of signal transduction inhibitors w ith endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 2003: 9:524s-532s.
29. Collins P. Webb C. Estrogen hits the surface. Nat Med 1999; 5:1130-1131.
30. Kousteni S. Han L. Chen J-R. Almeida M. Plotkin LI. Bellido T. Manolagas SC. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 2003: 111:1651-1664.
31. McDonnell DP. Norris JD. Connections and regulation of the human estrogen receptor. Science 2002: 296:1642-1644.
32. Lonard DM. Smith CL. Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions. Steroids 2002: 67:15-24.
33. Stoica GE. Franke TF. Wellstein A. Morgan E. Czubayko F. List H-J. Reiter R. Martin MB. Stoica A. Heregulin-βl regulates the estrogen receptor-agene expression and activity via the ErhB2/PI3-K/Akt pathway. Oncogene 2003: 22:2073-2087.
34. Labriola L. Salatino M. Proietti CJ. Peed A. Coso OA. Kornblihtt AR. Charreau EH. Elizalde PV. Heregulm induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErhB2 and mitogen-activated protein kinase activation in breast cancer cells. Mol Cell Biol 2003: 23:1095-1111.
35. Treeck O., Diedrich K., Ortmann O., The activ ation of an extracellular signul-rcsulaied kinase by oestradiol interferes w ith the effects of trastuzumab on HF.R2 sienalline in endometrial adenocarcinoma cell lines. Eur. J Cancer 2003: 39:1302-1309.
36. Bishop PC., Mvers T, Robey R., Fry DYV., Liu FT., Blagosklonnv MV., Bates SE., Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 2002: 21:119-127.
37. Lai H. Lin I. Nadji M. Lai S. Trapido E. Meng L. Mutations in the p53 tumor suppressor gene and early onset breast cancer. Cancer Biol & Ther 2002: 1: 31-36
38. Olivier M. Hainuut P. Tp53 mutation patterns in breast cancers: searching for clues ol env ironmental carcinogenesis. Cancer Biol 2001:11:353-360.
39. Liu F.T. Molecular oncodiagnoslics: where we are and where we need to go. J Clin Oncol 2003: 21:2052-2055.
40. Sorlie T. Perou CM. Tibshirani R. Aas T. Geisler S. Johnson H. Haslie T. Eisen MB. Van de Rijn M. Jeffrey SS. Thorsen T. Quisi H. Maiese JC. Brown PO. Botslein D. Lonning PE. Borresen-Dale A-L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sei (USA)2001: 98:10869-10874.
41. Gruvberger S. Ringner M. Chen Y. Panavally S. Saal LH. Borg A. Femo M. Peterson C. Meitzer PS. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001; 61:5979-5984.
42. Schafer JM. Lee ES. O’Regan RM. Yao K. Jordan VC. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymie mice. Clin Cancer Res 2000: 4373-4380.